Added to YB: 2026-01-15
Pitch date: 2026-01-13
BNTX [neutral]
BioNTech SE
-8.97%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany.
Market Cap
$19.9B
Pitch Price
$109.27
Price Target
N/A
Dividend
N/A
EV/EBITDA
-5.96
P/E
-16.75
EV/Sales
2.24
Sector
Biotechnology
Category
growth
BioNTech (BNTX Germany): a quiet revenue bridge year ahead of a defining oncology inflection
BNTX (update): 2026 shaping up as defining year w/ multiple late-stage oncology readouts across breast, lung, colorectal cancers. Covid revenue declining but $17B cash provides flexibility. No oncology revenue expected 2026, emphasis on clinical proof points. Success could shift narrative from optionality to execution as multi-asset oncology player.
Read full article (2 min)